Rodger Novak | Chief Executive Officer and Founder
CRISPR Therapeutics

Rodger Novak, Chief Executive Officer and Founder, CRISPR Therapeutics

Dr. Rodger Novak co-founded CRISPR Therapeutics together with Emmanuelle Charpentier and Shaun Foy. He is an experienced pharmaceutical and biotechnology executive and former University Professor at the Vienna Biocenter in Austria. He brings a combination of scientific experience, gained through his academic career, and a proven track record of successfully translating technologies into pharmaceutical products. In his most recent position, Rodger was Global Head, Anti-Infectives Research & Development at Sanofi, where he was responsible for small molecule and biologics R&D, including early drug discovery and clinical development. Before that he was a founder of Nabriva Therapeutics and served as its Chief Operating Officer for almost six years. He started his pharmceutical career at Sandoz (Novartis), where he was appointed as the deputy Head of the Antibiotic Research Institute. Rodger received his M.D. from the Philipps University in Marburg, Germany in 1993 and his foreign medical license for the U.S. in 1994. He was a postdoctoral fellow at The Rockefeller University, St. Jude Children’s Research Hospital and the Skirball Institute NYU Medical Center. During his academic career Rodger authored numerous publications, among them articles in NatureNature Medicine and Molecular Cell. Rodger is co-inventor of five patents.


World Orphan Drug Congress USA 2018 - Conference Day Two (General) @ 09:25

Keynote address: Translating CRISPR/Cas9 technology into transformative gene-based medicines for patients with serious diseases

  • In vivo and ex vivo treatments using CRISPR/Cas9 for different therapeutic indications
  • CRISPR/Cas9 potential to correct DNA changes in somatic (non germ line) cells in patients with serious disease and the road to clinical trials
  • Partnerships with other pharmaceutical companies to develop gene-editing-based therapeutics

back to speakers